TREM2 Modulator Compounds for Neurodegenerative Loss-of-Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a high unmet medical need for modulators of Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) to address neurodegenerative diseases such as Alzheimer's disease, Frontotemporal lobar degeneration, Parkinson's disease, Huntington disease, Nasu-Hakola disease, Multiple sclerosis, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathies, and Amyotrophic lateral sclerosis, as loss-of-function variants of TREM2 are associated with these conditions.
Innovation Solution
Development of compounds that modulate TREM2 activity, specifically represented by Formula (I) compounds and their pharmaceutically acceptable salts, which can be used to treat diseases associated with loss-of-function of TREM2, including neurodegenerative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If loss-of-function variants of TREM2 are present, then neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and other neurological disorders occur, but there are no effective treatments currently available
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of TREM2 ligands through systematic variation of molecular parameters (substituents, functional groups, molecular weight, lipophilicity). This allows optimization of binding affinity, selectivity, and pharmacological activity to create effective modulators that can restore or enhance TREM2 function in neurodegenerative diseases
Solution Approach 2:
The patent uses small molecule compounds as intermediaries that bind to TREM2 and modulate its signaling activity. These compounds act as mediators between the TREM2 receptor and downstream signaling pathways, enabling therapeutic control of microglial function without directly modifying the receptor structure itself
2Reliability
If TREM2 activity is modulated to treat neurodegenerative diseases, then therapeutic effect is achieved, but compound development and characterization requires extensive resources
Solution Approach 1:
The patent applies segmentation by dividing the TREM2 ligand family into distinct structural series (compounds of Formula I with specific R1-R5 substituents). This systematic classification allows independent optimization of each series' properties and enables parallel development of multiple candidates with different mechanisms of action, reducing overall development complexity
Solution Approach 2:
The patent employs parameter changes through defined structural variables (R1, R2, R3, R4, R5 substituents) that can be systematically varied to optimize compound properties. This parameter-based approach allows predictive modeling of pharmacological activity and facilitates prioritization of compounds for further development based on calculated properties rather than exhaustive screening
Data Source
AI summary
The present invention relates to compounds useful for modulating Triggering Receptor Expressed on Myeloid Cells-2 (“TREM2”). The invention also relates to the compounds for use in treatment of conditions related to loss of function of TREM2, such as neurodegenerative diseases, and to pharmaceutical compositions comprising the compounds.